Effects Of Atorvastatin And Ezetimibe On Dyslipidemia Of Type 2 DiabeticPatients

Authors: Imran Ali Sheikh, Muzaffar Ali Shaikh, Ikramudin Ujjan

LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, JAMSHORO/ HYDERABAD, SINDH PAKISTAN
LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, JAMSHORO/ HYDERABAD, SINDH PAKISTAN
LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES, JAMSHORO/ HYDERABAD, SINDH PAKISTAN

Volume 16 | Issue 2

Published: November 9, 2026

Abstract

To observe the effects of combination of atorvastatin and ezetimibe in type
2 diabetic patients attending. STUDY DESIGN : Prospective ; Observational study
PLACE AND DURATION: The study conducted from November 2007 to March 2008
in Medical OPDs, wards at Liaquat University of Medical & Health Sciences, Hyderabad
and consulting clinics of Sadder Hyderabad. PATIENTS METHODS: 50 patients were selected by random sampling, out of them 30 were males and 20 were females. The age range was 35-70 years. The mean BMI was 27. INCLUSION CRITERIA were type 2 diabetic patients already using atorvastatin for more than 1 month. The total cholesterol was more than 200 mg/dl, Triglycerides more than 150 mg/dl, LDL-c more than 150 mg/dl and HDL less than 35mg/dl. EXCLUSION CRITERIA were type 2 diabetic patients with cardiac , advanced renal disease or nephropathy. Any history to ezetimibe, atorvastatin allergy, pregnant and lactating mothers, type 1 diabetics or any type 2 diabetic patient using immunosuppressive drugs. All patients were taking oral hypoglycemic agents like Glibenclamide and metformin in combination or alone for more than 2 years. No patient was on insulin. Fasting blood sugar and lipid profile were done. The LFT was done before treatment and completion of the study. Lipid profile was checked on 0, 6 and 12 weeks.
The atorvastatin was given with dose of 20 mg and ezetimibe 10 mg once a day at bed
time. The data was tabulated and calculated on SPSS 15 . The p value less than 0.05
considered statically significant. RESULTS; After 12 weeks Total cholesterol was reduced 9% (p=<0.001), LDL-c was reduced 18%(p=<0.001) ,TG 12% (p=<0.001)and HDL increased 11%(p=<0.05) CONCLUSION. Diabetes dyslipidemia is an important cause of morbidity. Patients should be keeping on combination of atorvastatin and ezetimibe. This combination is well tolerated .

Keywords: diabetes Mellitus, dyslipidemia, atorvastatin and ezetimibe.

DOI: (All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.)

Download Full Text PDF